Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Tobacco plants have been enlisted as bioreactors for making what scientists hope will become the first vaccine for the norovirus, the cause of many food-poisoning outbreaks and the dreaded winter vomiting disease.

Using a production system that combines viruses, bacteria and plants to produce large quantities of vaccine rapidly, researchers at Arizona State University and biotech company Vaxx say they have a fast, cheap and reliable way to fight fast-changing pathogens like the norovirus.

With an estimated 23 to 74 million yearly cases in the U.S. alone, the norovirus is thought to be the second most common cause of infectious disease after the flu. Furthermore, like the flu, it has the ability to produce new strains every year or two, which has made it difficult to develop a vaccine.

Going through a lengthy and costly vaccine development process for a nonlethal virus that changes quickly presents a high financial risk for companies, says Charles Arntzen, one of the lead researchers on the project, who presented the work at this year’s fall meeting of the American Chemical Society in Washington, D.C.

“With the norovirus, a government mandate to vaccinate is unlikely, because it is inconvenient rather than a major death threat for people, meaning there would be no guaranteed market,” he says.

The technology used by Arntzen and his colleagues exploits the fact that plants are cheap to grow and incur little regulation compared with animal-based vaccine development systems, since plant-borne pathogens are not dangerous to humans. The new approach also addresses a number of shortcomings that have held back plant-based vaccine development in the past. In particular, the length of time it takes to make a transgenic plant that expresses enough vaccine proteins and the difficulty of processing plants in such a way that a stable, precisely dosed vaccine can be obtained.

To overcome the first challenge, the researchers developed a three-step system that allows faster production of foreign proteins in plants. First, genes that encode the proteins are engineered into an inactivated version of a plant virus, in this case the tobacco mosaic virus (TMV). Since TMV uses RNA instead of DNA as its genetic material–but genetic manipulation in the lab is done on DNA–the second step is to trick bacteria that can infect tobacco into producing a DNA version of the virus along with the vaccine genes. In step three, RNA copies of the viral genes are produced inside the infected plant cells and hijack their biochemical machinery to make copies of the desired protein. “Within 5 days [to] 2 weeks, the tobacco plant dies, but as it does so it is producing massive amounts of our protein, up to one gram per kilo of biomass,” says Arntzen.

0 comments about this story. Start the discussion »

Credit: Charles Arntzen

Tagged: Biomedicine, vaccine, pathogens, plants

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me